ARTICLE | Clinical News
Zalicus slides after dropping RA product
September 11, 2012 1:13 AM UTC
Zalicus Inc. (NASDAQ:ZLCS) fell $0.60 (43%) to $0.79 on Monday after discontinuing development of Synavive after it did not significantly reduce DAS28-CRP scores from baseline to week 12 vs. active comparator prednisolone in the Phase IIb SYNERGY trial to treat rheumatoid arthritis. The selective steroid amplifier containing dipyridamole and prednisolone did significantly reduce DAS28-CRP scores from baseline to week 12 vs. placebo. ...